1
|
Péczely L, Dusa D, Lénárd L, Ollmann T, Kertes E, Gálosi R, Berta B, Szabó Á, László K, Zagoracz O, Karádi Z, Kállai V. The antipsychotic agent sulpiride microinjected into the ventral pallidum restores positive symptom-like habituation disturbance in MAM-E17 schizophrenia model rats. Sci Rep 2024; 14:12305. [PMID: 38811614 PMCID: PMC11136981 DOI: 10.1038/s41598-024-63059-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Accepted: 05/24/2024] [Indexed: 05/31/2024] Open
Abstract
Dysfunction of subcortical D2-like dopamine receptors (D2Rs) can lead to positive symptoms of schizophrenia, and their analog, the increased locomotor activity in schizophrenia model MAM-E17 rats. The ventral pallidum (VP) is a limbic structure containing D2Rs. The D2R antagonist sulpiride is a widespread antipsychotic drug, which can alleviate positive symptoms in human patients. However, it is still not known how sulpiride can influence positive symptoms via VP D2Rs. We hypothesize that the microinjection of sulpiride into the VP can normalize hyperactivity in MAM-E17 rats. In addition, recently, we showed that the microinjection of sulpirid into the VP induces place preference in neurotypical rats. Thus, we aimed to test whether intra-VP sulpiride can also have a rewarding effect in MAM-E17 rats. Therefore, open field-based conditioned place preference (CPP) test was applied in neurotypical (SAL-E17) and MAM-E17 schizophrenia model rats to test locomotor activity and the potential locomotor-reducing and rewarding effects of sulpiride. Sulpiride was microinjected bilaterally in three different doses into the VP, and the controls received only vehicle. The results of the present study demonstrated that the increased locomotor activity of the MAM-E17 rats was caused by habituation disturbance. Accordingly, larger doses of sulpiride in the VP reduce the positive symptom-analog habituation disturbance of the MAM-E17 animals. Furthermore, we showed that the largest dose of sulpiride administered into the VP induced CPP in the SAL-E17 animals but not in the MAM-E17 animals. These findings revealed that VP D2Rs play an important role in the formation of positive symptom-like habituation disturbances in MAM-E17 rats.
Collapse
Affiliation(s)
- László Péczely
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary.
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary.
- Centre for Neuroscience, University of Pécs, Pécs, Hungary.
| | - Daniella Dusa
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - László Lénárd
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Molecular Neuroendocrinology and Neurophysiology Research Group, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Tamás Ollmann
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Neuropeptides, Cognition, Animal Models of Neuropsychiatric Disorders Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Erika Kertes
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Neuropeptides, Cognition, Animal Models of Neuropsychiatric Disorders Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Rita Gálosi
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Reinforcement Learning Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Beáta Berta
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Neuropeptides, Cognition, Animal Models of Neuropsychiatric Disorders Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Ádám Szabó
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
| | - Kristóf László
- Neuropeptides, Cognition, Animal Models of Neuropsychiatric Disorders Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Olga Zagoracz
- Neuropeptides, Cognition, Animal Models of Neuropsychiatric Disorders Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Zoltán Karádi
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Molecular Neuroendocrinology and Neurophysiology Research Group, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| | - Veronika Kállai
- Learning in Biological and Artificial Systems Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Neuropeptides, Cognition, Animal Models of Neuropsychiatric Disorders Research Group, Institute of Physiology, Medical School, University of Pécs, Pécs, Hungary
- Institute of Physiology, Medical School, University of Pécs, Szigeti Str. 12, P.O. Box: 99, 7602, Pécs, Hungary
- Centre for Neuroscience, University of Pécs, Pécs, Hungary
| |
Collapse
|
2
|
Schamiloglu S, Lewis E, Keeshen CM, Hergarden AC, Bender KJ, Whistler JL. Arrestin-3 Agonism at Dopamine D 3 Receptors Defines a Subclass of Second-Generation Antipsychotics That Promotes Drug Tolerance. Biol Psychiatry 2023; 94:531-542. [PMID: 36931452 PMCID: PMC10914650 DOI: 10.1016/j.biopsych.2023.03.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 02/09/2023] [Accepted: 03/02/2023] [Indexed: 03/19/2023]
Abstract
BACKGROUND Second-generation antipsychotics (SGAs) are frontline treatments for serious mental illness. Often, individual patients benefit only from some SGAs and not others. The mechanisms underlying this unpredictability in treatment efficacy remain unclear. All SGAs bind the dopamine D3 receptor (D3R) and are traditionally considered antagonists for dopamine receptor signaling. METHODS Here, we used a combination of two-photon calcium imaging, in vitro signaling assays, and mouse behavior to assess signaling by SGAs at D3R. RESULTS We report that some clinically important SGAs function as arrestin-3 agonists at D3R, resulting in modulation of calcium channels localized to the site of action potential initiation in prefrontal cortex pyramidal neurons. We further show that chronic treatment with an arrestin-3 agonist SGA, but not an antagonist SGA, abolishes D3R function through postendocytic receptor degradation by GASP1 (G protein-coupled receptor-associated sorting protein-1). CONCLUSIONS These results implicate D3R-arrestin-3 signaling as a source of SGA variability, highlighting the importance of including arrestin-3 signaling in characterizations of drug action. Furthermore, they suggest that postendocytic receptor trafficking that occurs during chronic SGA treatment may contribute to treatment efficacy.
Collapse
Affiliation(s)
- Selin Schamiloglu
- Neuroscience Graduate Program, University of California San Francisco, San Francisco, California
| | - Elinor Lewis
- Neuroscience Graduate Group, University of California Davis, Davis, California; Center for Neuroscience, University of California Davis, Davis, California
| | - Caroline M Keeshen
- Neuroscience Graduate Group, University of California Davis, Davis, California; Center for Neuroscience, University of California Davis, Davis, California
| | - Anne C Hergarden
- Center for Neuroscience, University of California Davis, Davis, California
| | - Kevin J Bender
- Neuroscience Graduate Program, University of California San Francisco, San Francisco, California; Department of Neurology, Kavli Institute for Fundamental Neuroscience, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California.
| | - Jennifer L Whistler
- Center for Neuroscience, University of California Davis, Davis, California; Department of Physiology and Membrane Biology, University of California Davis School of Medicine, Davis, California.
| |
Collapse
|
3
|
de Bartolomeis A, Ciccarelli M, De Simone G, Mazza B, Barone A, Vellucci L. Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia. Int J Mol Sci 2023; 24:ijms24065945. [PMID: 36983018 PMCID: PMC10051989 DOI: 10.3390/ijms24065945] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 03/15/2023] [Accepted: 03/17/2023] [Indexed: 03/30/2023] Open
Abstract
Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide and is conceptualized as a disorder of synaptic plasticity and brain connectivity. Antipsychotics are the primary pharmacological treatment after more than sixty years after their introduction in therapy. Two findings hold true for all presently available antipsychotics. First, all antipsychotics occupy the dopamine D2 receptor (D2R) as an antagonist or partial agonist, even if with different affinity; second, D2R occupancy is the necessary and probably the sufficient mechanism for antipsychotic effect despite the complexity of antipsychotics' receptor profile. D2R occupancy is followed by coincident or divergent intracellular mechanisms, implying the contribution of cAMP regulation, β-arrestin recruitment, and phospholipase A activation, to quote some of the mechanisms considered canonical. However, in recent years, novel mechanisms related to dopamine function beyond or together with D2R occupancy have emerged. Among these potentially non-canonical mechanisms, the role of Na2+ channels at the dopamine at the presynaptic site, dopamine transporter (DAT) involvement as the main regulator of dopamine concentration at synaptic clefts, and the putative role of antipsychotics as chaperones for intracellular D2R sequestration, should be included. These mechanisms expand the fundamental role of dopamine in schizophrenia therapy and may have relevance to considering putatively new strategies for treatment-resistant schizophrenia (TRS), an extremely severe condition epidemiologically relevant and affecting almost 30% of schizophrenia patients. Here, we performed a critical evaluation of the role of antipsychotics in synaptic plasticity, focusing on their canonical and non-canonical mechanisms of action relevant to the treatment of schizophrenia and their subsequent implication for the pathophysiology and potential therapy of TRS.
Collapse
Affiliation(s)
- Andrea de Bartolomeis
- Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples "Federico II", 80131 Naples, Italy
| | - Mariateresa Ciccarelli
- Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples "Federico II", 80131 Naples, Italy
| | - Giuseppe De Simone
- Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples "Federico II", 80131 Naples, Italy
| | - Benedetta Mazza
- Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples "Federico II", 80131 Naples, Italy
| | - Annarita Barone
- Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples "Federico II", 80131 Naples, Italy
| | - Licia Vellucci
- Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive Sciences and Dentistry, University Medical School of Naples "Federico II", 80131 Naples, Italy
| |
Collapse
|
4
|
Grasing KW, Burnell K, De A. Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders. Behav Pharmacol 2022; 33:238-248. [PMID: 35324488 PMCID: PMC9149059 DOI: 10.1097/fbp.0000000000000672] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Lorcaserin is a modestly selective agonist for 2C serotonin receptors (5-HT2CR). Despite early promising data, it recently failed to facilitate cocaine abstinence in patients and has been compared with dopamine antagonist medications (antipsychotics). Here, we review the effects of both classes on drug reinforcement. In addition to not being effective treatments for cocaine use disorder, both dopamine antagonists and lorcaserin can have biphasic effects on dopamine and reward behavior. Lower doses can cause enhanced drug taking with higher doses causing reductions. This biphasic pattern is shared with certain stimulants, opioids, and sedative-hypnotics, as well as compounds without abuse potential that include agonists for muscarinic and melatonin receptors. Additional factors associated with decreased drug taking include intermittent dosing for dopamine antagonists and use of progressive-ratio schedules for lorcaserin. Clinically relevant doses of lorcaserin were much lower than those that inhibited cocaine-reinforced behavior and can also augment this same behavior in different species. Diminished drug-reinforced behavior only occurred in animals after higher doses that are not suitable for use in patients. In conclusion, drugs of abuse and related compounds often act as biphasic modifiers of reward behavior, especially when evaluated over a broad range of doses. This property may reflect the underlying physiology of the reward system, allowing homeostatic influences on behavior.
Collapse
Affiliation(s)
- Ken W Grasing
- Substance Use Research Laboratory, Research Service, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri
- Division of Clinical Pharmacology, Department of Medicine, University of Kansas School of Medicine, Kansas City, Kansas, USA
| | - Kim Burnell
- Substance Use Research Laboratory, Research Service, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri
| | - Alok De
- Substance Use Research Laboratory, Research Service, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri
| |
Collapse
|
5
|
Enhancing the Antipsychotic Effect of Risperidone by Increasing Its Binding Affinity to Serotonin Receptor via Picric Acid: A Molecular Dynamics Simulation. Pharmaceuticals (Basel) 2022; 15:ph15030285. [PMID: 35337083 PMCID: PMC8952232 DOI: 10.3390/ph15030285] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 02/17/2022] [Accepted: 02/23/2022] [Indexed: 02/04/2023] Open
Abstract
The aim of this study was to assess the utility of inexpensive techniques in evaluating the interactions of risperidone (Ris) with different traditional -acceptors, with subsequent application of the findings into a Ris pharmaceutical formulation with improved therapeutic properties. Molecular docking calculations were performed using Ris and its different charge-transfer complexes (CT) with picric acid (PA), 2,3-dichloro-5,6-dicyanop-benzoquinon (DDQ), tetracyanoquinodimethane (TCNQ), tetracyano ethylene (TCNE), tetrabromo-pquinon (BL), and tetrachloro-p-quinon (CL), as donors, and three receptors (serotonin, dopamine, and adrenergic) as acceptors to study the comparative interactions among them. To refine the docking results and further investigate the molecular processes of receptor–ligand interactions, a molecular dynamics simulation was run with output obtained from AutoDock Vina. Among all investigated complexes, the [(Ris) (PA)]-serotonin (CTcS) complex showed the highest binding energy. Molecular dynamics simulation of the 100 ns run revealed that both the Ris-serotonin (RisS) and CTcS complexes had a stable conformation; however, the CTcS complex was more stable.
Collapse
|
6
|
Modulation of mGlu5 improves sensorimotor gating deficits in rats neonatally treated with quinpirole through changes in dopamine D2 signaling. Pharmacol Biochem Behav 2021; 211:173292. [PMID: 34710401 DOI: 10.1016/j.pbb.2021.173292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/19/2021] [Accepted: 10/20/2021] [Indexed: 12/19/2022]
Abstract
This study analyzed whether the positive allosteric modulator of metabotropic glutamate receptor type 5 (mGlu5) 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamide (CDPPB) would alleviate deficits in prepulse inhibition (PPI) and affect dopamine (DA) D2 signaling in the dorsal striatum and prefrontal cortex (PFC) in the neonatal quinpirole (NQ) model of schizophrenia (SZ). Male and female Sprague-Dawley rats were neonatally treated with either saline (NS) or quinpirole HCL (1 mg/kg; NQ), a DAD2 receptor agonist, from postnatal days (P) 1-21. Rats were raised to P44 and behaviorally tested on PPI from P44-P48. Before each trial, rats were subcutaneous (sc) administered saline or CDPPB (10 mg/kg or 30 mg/kg). On P50, rats were given a spontaneous locomotor activity test after CDPPB or saline administration. On P51, the dorsal striatum and PFC were evaluated for both arrestin-2 (βA-2) and phospho-AKT protein levels. NQ-treated rats demonstrated a significant deficit in PPI, which was alleviated to control levels by the 30 mg/kg dose of CDPPB. There were no significant effects of CDPPB on locomotor activity. NQ treatment increased βA-2 and decreased phospho-AKT in both the dorsal striatum and PFC, consistent with an increase DAD2 signaling. The 30 mg/kg dose of CDPPB significantly reversed changes in βA-2 in the dorsal striatum and PFC and phospho-AKT in the PFC equivalent to controls. Both doses of CDPPB produced a decrease of phospho-AKT in the PFC compared to controls. This study revealed that a mGlu5 positive allosteric modulator was effective to alleviate PPI deficits and striatal DAD2 signaling in the NQ model of SZ.
Collapse
|
7
|
Gill WD, Burgess KC, Vied C, Brown RW. Transgenerational evidence of increases in dopamine D2 receptor sensitivity in rodents: Impact on sensorimotor gating, the behavioral response to nicotine and BDNF. J Psychopharmacol 2021; 35:1188-1203. [PMID: 34291671 PMCID: PMC9169618 DOI: 10.1177/02698811211033927] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND/AIMS Neonatal quinpirole (NQ) treatment to rats increases dopamine D2 (DAD2) receptor sensitivity in adult animals. We investigated if increased DAD2 sensitivity would be passed to the next (F1) generation, and if these animals demonstrated sensorimotor gating deficits and enhanced behavioral responses to nicotine. METHODS Male and female rats were intraperitoneal (IP) administered quinpirole (1 mg/kg) or saline (NS) from postnatal day (P)1-21. Animals were either behaviorally tested (F0) or raised to P60 and mated, creating F1 offspring. RESULTS Experiment 1 revealed that F1 generation animals that were the offspring of at least one NQ-treated founder increased yawning behavior, a DAD2-mediated behavioral event, in response to acute quinpirole (0.1 mg/kg). F1 generation rats also demonstrated increased striatal β arrestin-2 and decreased phospho-AKT signaling, consistent with increased G-protein independent DAD2 signaling, which was equal to F0 NQ-treated founders, although this was not observed in all groups. RNA-Seq analysis revealed significant gene expression changes in the F1 generation that were offspring of both NQ-treated founders compared to F0 NQ founders and controls, with enrichment in sensitivity to stress hormones and cell signaling pathways. In Experiment 2, all F1 generation offspring demonstrated sensorimotor gating deficits compared to controls, which were equivalent to F0 NQ-treated founders. In Experiment 3, all F1 generation animals demonstrated enhanced nicotine behavioral sensitization and nucleus accumbens (NAcc) brain-derived neurotrophic factor (BDNF) protein. Further, F1 generation rats demonstrated enhanced adolescent nicotine conditioned place preference equivalent to NQ-treated founders conditioned with nicotine. CONCLUSIONS This represents the first demonstration of transgenerational effects of increased DAD2 sensitivity in a rodent model.
Collapse
Affiliation(s)
- Wesley Drew Gill
- James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA
| | - Katherine C Burgess
- James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA
| | - Cynthia Vied
- Translational Science Laboratory, Florida State University College of Medicine, Tallahassee, FL, USA
| | - Russell W Brown
- James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA
| |
Collapse
|
8
|
Inkster JAH, Sromek AW, Akurathi V, Neumeyer JL, Packard AB. The Non-Anhydrous, Minimally Basic Synthesis of the Dopamine D 2 Agonist [18F]MCL-524. CHEMISTRY (BASEL, SWITZERLAND) 2021; 3:1047-1056. [PMID: 37830058 PMCID: PMC10569134 DOI: 10.3390/chemistry3030075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 10/14/2023]
Abstract
The dopamine D2 agonist MCL-524 is selective for the D2 receptor in the high-affinity state (D2high), and, therefore, the PET analogue, [18F]MCL-524, may facilitate the elucidation of the role of D2high in disorders such as schizophrenia. However, the previously reported synthesis of [18F]MCL-524 proved difficult to replicate and was lacking experimental details. We therefore developed a new synthesis of [18F]MCL-524 using a "non-anhydrous, minimally basic" (NAMB) approach. In this method, [18F]F- is eluted from a small (10-12 mg) trap-and-release column with tetraethylammonium tosylate (2.37 mg) in 7:3 MeCN:H2O (0.1 mL), rather than the basic carbonate or bicarbonate solution that is most often used for [18F]F- recovery. The tosylated precursor (1 mg) in 0.9 mL anhydrous acetonitrile was added directly to the eluate, without azeotropic drying, and the solution was heated (150 °C/15 min). The catechol was then deprotected with the Lewis acid In(OTf)3 (10 equiv.; 150 °C/20 min). In contrast to deprotection with protic acids, Lewis-acid-based deprotection facilitated the efficient removal of byproducts by HPLC and eliminated the need for SPE extraction prior to HPLC purification. Using the NAMB approach, [18F]MCL-524 was obtained in 5-9% RCY (decay-corrected, n = 3), confirming the utility of this improved method for the multistep synthesis of [18F]MCL-524 and suggesting that it may applicable to the synthesis of other 18F-labeled radiotracers.
Collapse
Affiliation(s)
- James A. H. Inkster
- Division of Nuclear Medicine and Molecular Imaging, Boston Children’s Hospital, 300 Longwood Ave., Boston, MA 02115, USA
- Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA
| | - Anna W. Sromek
- Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA
- Division of Basic Neuroscience, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA
| | - Vamsidhar Akurathi
- Division of Nuclear Medicine and Molecular Imaging, Boston Children’s Hospital, 300 Longwood Ave., Boston, MA 02115, USA
- Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA
| | - John L. Neumeyer
- Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA
- Division of Basic Neuroscience, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA
| | - Alan B. Packard
- Division of Nuclear Medicine and Molecular Imaging, Boston Children’s Hospital, 300 Longwood Ave., Boston, MA 02115, USA
- Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA
| |
Collapse
|
9
|
Characterization of dopamine D 2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia. Pharmacol Rep 2021; 73:1136-1146. [PMID: 34196951 PMCID: PMC8413194 DOI: 10.1007/s43440-021-00305-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 06/16/2021] [Accepted: 06/24/2021] [Indexed: 11/04/2022]
Abstract
Background Alterations of dopamine D1 (D1R) and D2 receptor (D2R) are proposed in schizophrenia but brain neuroimaging and postmortem studies have shown controversial results in relation to D1R and D2R density. Besides, scarce information on the functionality of brain D1R and D2R is available. The present study characterized G-protein activation by D1R and D2R agonists in postmortem human brain. Furthermore, D2R functional status was compared between schizophrenia and control subjects. Methods G-protein receptor coupling was assessed in control caudate nucleus and frontal cortex by [35S]GTPγS-binding stimulation induced by increasing concentrations (10–10–10–3 M) of dopamine, and the selective dopaminergic agonists SKF38393 (D1R) and NPA (D2R). Concentration–response curves to NPA stimulation of [35S]GTPγS binding were analyzed in antipsychotic-free (n = 10) and antipsychotic-treated (n = 7) schizophrenia subjects and matched controls (n = 17). Results In caudate, [35S]GTPγS-binding responses to agonists were compatible with the existence of functional D2R. In contrast, stimulations in cortex showed responses that did not correspond to D1R or D2R. [35S]GTPγS-binding activation by NPA in caudate displayed biphasic curves with similar profile in schizophrenia (EC50H = 7.94 nM; EC50L = 7.08 μM) and control (EC50H = 7.24 nM; EC50L = 15.14 μM) subjects. The presence or absence of antipsychotic medication did not influence the pharmacological parameters. Conclusions Feasibility of functional evaluation of dopamine receptors in postmortem human brain by conventional [35S]GTPγS-binding assays appears to be restricted to signalling through inhibitory Gi/o proteins. These findings provide functional information about brain D2R status in subjects with schizophrenia and do not support the existence of D2R supersensitive in this mental disorder. Supplementary Information The online version contains supplementary material available at 10.1007/s43440-021-00305-4.
Collapse
|
10
|
Sagheddu C, Traccis F, Serra V, Congiu M, Frau R, Cheer JF, Melis M. Mesolimbic dopamine dysregulation as a signature of information processing deficits imposed by prenatal THC exposure. Prog Neuropsychopharmacol Biol Psychiatry 2021; 105:110128. [PMID: 33031862 DOI: 10.1016/j.pnpbp.2020.110128] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 10/02/2020] [Accepted: 10/03/2020] [Indexed: 11/17/2022]
Abstract
Cannabis is the illicit drug most widely used by pregnant women worldwide. Its growing acceptance and legalization have markedly increased the risks of child psychopathology, including psychotic-like experiences, which lowers the age of onset for a first psychotic episode. As the majority of patients with schizophrenia go through a premorbid condition long before this occurs, understanding neurobiological underpinnings of the prodromal stage of the disease is critical to improving illness trajectories and therapeutic outcomes. We have previously shown that male rat offspring prenatally exposed to Δ9-tetrahydrocannabinol (THC), a rat model of prenatal cannabinoid exposure (PCE), exhibit extensive molecular and synaptic changes in dopaminergic neurons of the ventral tegmental area (VTA), converging on a hyperdopaminergic state. This leads to a silent psychotic-like endophenotype that is unmasked by a single exposure to THC. Here, we further characterized the VTA dopamine neuron and sensorimotor gating functions of PCE rats exposed to acute stress or a challenge of the D2 receptor agonist apomorphine, by using in vivo single-unit extracellular recordings and Prepulse Inhibition (PPI) analyses. At pre-puberty, PCE male rat offspring display a reduced population activity of VTA dopamine neurons in vivo, the majority of which are tonically active. PCE male progeny also exhibit enhanced sensitivity to dopamine D2 (DAD2) receptor activation and a vulnerability to acute stress, which is associated with compromised sensorimotor gating functions. This data extends our knowledge of the multifaceted sequelae imposed by PCE in the mesolimbic dopamine system of male pre-adolescent rats, which renders a neural substrate highly susceptible to subsequent challenges that may trigger psychotic-like outcomes.
Collapse
Affiliation(s)
- Claudia Sagheddu
- Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Italy
| | - Francesco Traccis
- Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Italy
| | - Valeria Serra
- Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Italy
| | - Mauro Congiu
- Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Italy
| | - Roberto Frau
- Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Italy
| | - Joseph F Cheer
- Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Miriam Melis
- Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Italy.
| |
Collapse
|
11
|
Valle-León M, Callado LF, Aso E, Cajiao-Manrique MM, Sahlholm K, López-Cano M, Soler C, Altafaj X, Watanabe M, Ferré S, Fernández-Dueñas V, Menchón JM, Ciruela F. Decreased striatal adenosine A 2A-dopamine D 2 receptor heteromerization in schizophrenia. Neuropsychopharmacology 2021; 46:665-672. [PMID: 33010795 PMCID: PMC8027896 DOI: 10.1038/s41386-020-00872-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 08/04/2020] [Accepted: 08/26/2020] [Indexed: 02/04/2023]
Abstract
According to the adenosine hypothesis of schizophrenia, the classically associated hyperdopaminergic state may be secondary to a loss of function of the adenosinergic system. Such a hypoadenosinergic state might either be due to a reduction of the extracellular levels of adenosine or alterations in the density of adenosine A2A receptors (A2ARs) or their degree of functional heteromerization with dopamine D2 receptors (D2R). In the present study, we provide preclinical and clinical evidences for this latter mechanism. Two animal models for the study of schizophrenia endophenotypes, namely the phencyclidine (PCP) mouse model and the A2AR knockout mice, were used to establish correlations between behavioural and molecular studies. In addition, a new AlphaLISA-based method was implemented to detect native A2AR-D2R heteromers in mouse and human brain. First, we observed a reduction of prepulse inhibition in A2AR knockout mice, similar to that observed in the PCP animal model of sensory gating impairment of schizophrenia, as well as a significant upregulation of striatal D2R without changes in A2AR expression in PCP-treated animals. In addition, PCP-treated animals showed a significant reduction of striatal A2AR-D2R heteromers, as demonstrated by the AlphaLISA-based method. A significant and pronounced reduction of A2AR-D2R heteromers was next demonstrated in postmortem caudate nucleus from schizophrenic subjects, even though both D2R and A2AR were upregulated. Finally, in PCP-treated animals, sub-chronic administration of haloperidol or clozapine counteracted the reduction of striatal A2AR-D2R heteromers. The degree of A2AR-D2R heteromer formation in schizophrenia might constitute a hallmark of the illness, which indeed should be further studied to establish possible correlations with chronic antipsychotic treatments.
Collapse
Affiliation(s)
- Marta Valle-León
- grid.5841.80000 0004 1937 0247Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Luis F. Callado
- grid.11480.3c0000000121671098Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain ,grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Instituto Salud Carlos III, Madrid, Spain ,Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| | - Ester Aso
- grid.5841.80000 0004 1937 0247Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
| | - María M. Cajiao-Manrique
- grid.5841.80000 0004 1937 0247Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.412041.20000 0001 2106 639XBordeaux International Neuroscience Master, University of Bordeaux, Bordeaux, France
| | - Kristoffer Sahlholm
- grid.5841.80000 0004 1937 0247Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.4714.60000 0004 1937 0626Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden ,grid.12650.300000 0001 1034 3451Department of Integrative Medical Biology, Umeå University, Umeå, Sweden
| | - Marc López-Cano
- grid.5841.80000 0004 1937 0247Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Concepció Soler
- grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.5841.80000 0004 1937 0247Immunology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Xavier Altafaj
- grid.5841.80000 0004 1937 0247Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Masahiko Watanabe
- grid.39158.360000 0001 2173 7691Department of Anatomy, Hokkaido University School of Medicine, Sapporo, 060-0818 Japan
| | - Sergi Ferré
- Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
| | - Víctor Fernández-Dueñas
- grid.5841.80000 0004 1937 0247Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
| | - José M. Menchón
- grid.413448.e0000 0000 9314 1427Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Instituto Salud Carlos III, Madrid, Spain ,grid.411129.e0000 0000 8836 0780Department of Psychiatry, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.418284.30000 0004 0427 2257Psychiatry and Mental Health Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain ,grid.5841.80000 0004 1937 0247Department of Clinical Sciences, School of Medicine, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Francisco Ciruela
- Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, UB, L'Hospitalet de Llobregat, Barcelona, Spain. .,Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
| |
Collapse
|
12
|
Kesserwani H. Delusional Infestation Secondary to the Dopamine Agonist Ropirinole in a Patient With Parkinson's Disease: A Case Report With an Outline of the Biology of Psychosis. Cureus 2021; 13:e12880. [PMID: 33633909 PMCID: PMC7899248 DOI: 10.7759/cureus.12880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/23/2021] [Indexed: 11/05/2022] Open
Abstract
Delusional infestation (DI) is a thought disorder, a delusion that one is infested with pathogens. Remarkably, these patients do not typically exhibit symptoms of anxiety or depression. The role of the dopamine D2 receptor is central to the idea of psychosis. In this article, we present a case of ropirinole-induced delusional skin infestation in a patient with Parkinson's disease, that was reversible with drug discontinuation. We seize upon this opportunity to discuss the pathology of the dopamine receptors, the glutamate N-methyl D-aspartate (NMDA) receptors and the serotonin 5-hydroxytryptamine (5HT-2A) receptors in the generation of psychosis. We outline the fundamental pharmacodynamical differences between the typical and atypical anti-psychotics that will help us understand how these agents work favorably and adversely. We also briefly review the neuroradialogy of psychosis and adumbrate on the mismatch between the meso-limbic system (motivational) and the salience network (valence) as the driver of the psychotic phenomenon.
Collapse
|
13
|
Takase M, Kimura H, Kanahara N, Nakata Y, Iyo M. Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis. J Psychopharmacol 2020; 34:540-547. [PMID: 31961236 DOI: 10.1177/0269881119900982] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND Patients with first-episode psychosis respond well to initial antipsychotic treatment, but among patients experiencing a relapse of psychosis, the response rate falls to approximately 30%. The mechanism of this discrepancy has not been clarified, but the development of dopamine supersensitivity psychosis with the underlying up-regulation of post-synaptic dopamine D2 receptors could be involved in this lesser response. It is uncertain whether elevated dopamine synthesis and release occurs in patients with dopamine supersensitivity psychosis, in contrast to those with first-episode psychosis. PATIENTS AND METHODS We examined a first-episode psychosis group (n=6) and a chronic schizophrenia group, i.e. patients experiencing relapse (n=23) including those who relapsed due to dopamine supersensitivity psychosis (n=18). Following the initiation of treatment, we measured the patients' blood concentrations of homovanillic acid and 3-methoxy-4-hydroxyphenylglycol at two weeks and four weeks after the baseline measurements. RESULTS The first-episode psychosis group tended to show decreased homovanillic acid, accompanied by an improvement of symptoms. The chronic schizophrenia group showed no alteration of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol over the treatment period. These results were the same in the dopamine supersensitivity psychosis patients alone. CONCLUSIONS Our findings suggest that unlike first-episode psychosis, the release of dopamine from presynaptic neurons did not increase in relapse episodes in the patients with dopamine supersensitivity psychosis. This indirectly indicates that the development of supersensitivity of post-synapse dopamine D2 receptor is involved in relapse in dopamine supersensitivity psychosis patients.
Collapse
Affiliation(s)
- Masayuki Takase
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
| | - Hisoshi Kimura
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.,Department of Psychiatry, Gakuji-kai Kimura Hospital, Chiba, Japan
| | - Nobuhisa Kanahara
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.,Center for Forensic Mental Health, Chiba University, Chiba, Japan
| | - Yusuke Nakata
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
| | - Masaomi Iyo
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
| |
Collapse
|
14
|
Faron-Górecka A, Kuśmider M, Solich J, Górecki A, Dziedzicka-Wasylewska M. Genetic variants in dopamine receptors influence on heterodimerization in the context of antipsychotic drug action. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2019; 169:279-296. [PMID: 31952689 DOI: 10.1016/bs.pmbts.2019.11.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Human dopamine D2 receptor (D2R) gene has polymorphic variants, three of them alter its amino acid sequence: Val96Ala, Pro310Ser and Ser311Cys. Their functional role never became the object of extensive studies, even though there are some evidence that they correlate with schizophrenia. The present work reviews data indicating that these mutations play a role in dimer formation with dopamine D1 receptor (D1R), with the strongest effect observed for Ser311Cys variant. Similarly, the affinity for antipsychotic drugs of this genetic variant depends on whether it is expressed together with D1R or not. Better understanding of altered ability of genetic variants of D2R to form dimers with D1R, as well as of altered affinity for antipsychotic drugs, depending on the absence or presence of the second dopamine receptor is of great importance-since these two receptors are not always co-expressed in the same cell. It may well be that targeting new compounds toward the D1R-D2R dimers, which the most probably form under conditions of excessive dopamine release, will result in antipsychotic drugs devoid of serious side effects.
Collapse
Affiliation(s)
- Agata Faron-Górecka
- Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
| | - Maciej Kuśmider
- Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
| | - Joanna Solich
- Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
| | - Andrzej Górecki
- Department of Physical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
| | - Marta Dziedzicka-Wasylewska
- Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland; Department of Physical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
| |
Collapse
|
15
|
Clark SD, Abi-Dargham A. The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence. Biol Psychiatry 2019; 86:502-511. [PMID: 31376930 DOI: 10.1016/j.biopsych.2019.05.012] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 02/25/2019] [Accepted: 05/05/2019] [Indexed: 01/17/2023]
Abstract
Schizophrenia is a debilitating mental illness that affects approximately 1% of the world's population. Despite much research in its neurobiology to aid in developing new treatments, little progress has been made. One system that has not received adequate attention is the kappa opioid system and its potential role in the emergence of symptoms, as well as its therapeutic potential. Here we present an overview of the kappa system and review various lines of evidence derived from clinical studies for dynorphin and kappa opioid receptor involvement in the pathology of both the positive and negative symptoms of schizophrenia. This overview includes evidence for the psychotomimetic effects of kappa opioid receptor agonists in healthy volunteers and their reversal by the pan-opioid antagonists naloxone and naltrexone and evidence for a therapeutic benefit in schizophrenia for 4 pan-opioid antagonists. We describe the interactions between kappa opioid receptors and the dopaminergic pathways that are disrupted in schizophrenia and the histologic evidence suggesting abnormal kappa opioid receptor signaling in schizophrenia. We conclude by discussing future directions.
Collapse
Affiliation(s)
- Samuel David Clark
- Columbia University Medical Center, New York; Terran Biosciences Inc., New York.
| | - Anissa Abi-Dargham
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York
| |
Collapse
|
16
|
Sepe FN, Chiasserini D, Parnetti L. Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies. FUTURE NEUROLOGY 2018. [DOI: 10.2217/fnl-2018-0003] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Lipids are fundamental components of brain cells as they are involved in several essential processes like remodeling of plasma membrane, synaptic function and receptor–ligand interactions. Systemic and brain alterations in lipid metabolism have been linked to the pathogenesis of neurodegenerative disorders like dementia and parkinsonisms. Intracellular transport of lipids is regulated by fatty acid-binding proteins. Recently, a member of this family, the fatty acid-binding protein 3 has been proposed as a potential biomarker across a range of neurodegenerative diseases, including Alzheimer's disease and dementia with Lewy bodies. In this special report, we describe recent progresses in characterizing the role of fatty acid-binding protein 3 in neurodegeneration and its putative role as biomarker measurable in biological fluids.
Collapse
Affiliation(s)
- Federica Nicoletta Sepe
- Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy
| | - Davide Chiasserini
- Stoller Biomarker Discovery Centre, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
| | - Lucilla Parnetti
- Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy
| |
Collapse
|
17
|
Veselinović T, Vernaleken I, Janouschek H, Cumming P, Paulzen M, Mottaghy FM, Gründer G. The role of striatal dopamine D 2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology (Berl) 2018; 235:2221-2232. [PMID: 29717334 DOI: 10.1007/s00213-018-4916-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 04/18/2018] [Indexed: 10/17/2022]
Abstract
OBJECTIVE A considerable body of research links cognitive function to dopaminergic transmission in the prefrontal cortex, but less is known about cognition in relation to striatal dopamine D2/3 receptors in unmedicated patients with psychosis. METHODS We investigated this association by obtaining PET recordings with the high-affinity D2/3 antagonist ligand [18F] fallypride in 15 medication-free patients with schizophrenia and 11 healthy controls. On the day of PET scanning, we undertook comprehensive neuropsychological testing and assessment of psychopathology using the Positive and Negative Syndrome Scale (PANSS). RESULTS The patients' performance in cognitive tests was significantly impaired in almost all domains. Irrespective of medication history, the mean [18F] fallypride binding potential (BPND) in the patient group tended to be globally 5-10% higher than that of the control group, but without reaching significance in any brain region. There were significant positive correlations between individual patient performance in the Trail Making Test (TMT(A) and TMT(B)) and Digit-Symbol-Substitution-Test with regional [18F] fallypride BPND, which remained significant after Bonferroni correction for the TMT(A) in caudate nucleus (CN) and for the TMT(B) in CN and putamen. No such correlations were evident in the control group. DISCUSSION The association between better cognitive performance and greater BPND in schizophrenia patients may imply that relatively lower receptor occupancy by endogenous dopamine favors better sparing of cognitive function. Absence of comparable correlations in healthy controls could indicate a greater involvement of signaling at dopamine D2/3 receptors in certain cognitive functions in schizophrenia patients than in healthy controls.
Collapse
Affiliation(s)
- Tanja Veselinović
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. .,Jülich Aachen Research Alliance JARA, Translational Brain Medicine, Jülich, Germany.
| | - Ingo Vernaleken
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany.,Jülich Aachen Research Alliance JARA, Translational Brain Medicine, Jülich, Germany
| | - Hildegard Janouschek
- Department of Psychiatry and Iowa Neuroscience Institute, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.,Department of Neurology, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Paul Cumming
- School of Psychology and Counselling and IHBI, Queensland University of Technology, and QIMR-Berghofer Institute, Brisbane, Australia
| | - Michael Paulzen
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany.,Jülich Aachen Research Alliance JARA, Translational Brain Medicine, Jülich, Germany.,Alexianer Hospital Aachen, Aachen, Germany
| | - Felix M Mottaghy
- Department of Nuclear Medicine, Medical Faculty, RWTH Aachen University, Aachen, Germany.,Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands
| | - Gerhard Gründer
- Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
18
|
Kubota M, Nagashima T, Takano H, Kodaka F, Fujiwara H, Takahata K, Moriguchi S, Kimura Y, Higuchi M, Okubo Y, Takahashi H, Ito H, Suhara T. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. Int J Neuropsychopharmacol 2017; 20:928-935. [PMID: 29016872 PMCID: PMC5737675 DOI: 10.1093/ijnp/pyx063] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Accepted: 07/19/2017] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Dopamine D2 receptors are reported to have high-affinity (D2High) and low-affinity (D2Low) states. Although an increased proportion of D2High has been demonstrated in animal models of schizophrenia, few clinical studies have investigated this alteration of D2High in schizophrenia in vivo. METHODS Eleven patients with schizophrenia, including 10 antipsychotic-naive and 1 antipsychotic-free individuals, and 17 healthy controls were investigated. Psychopathology was assessed by Positive and Negative Syndrome Scale, and a 5-factor model was used. Two radioligands, [11C]raclopride and [11C]MNPA, were employed to quantify total dopamine D2 receptor and D2High, respectively, in the striatum by measuring their binding potentials. Binding potential values of [11C]raclopride and [11C]MNPA and the binding potential ratio of [11C]MNPA to [11C]raclopride in the striatal subregions were statistically compared between the 2 diagnostic groups using multivariate analysis of covariance controlling for age, gender, and smoking. Correlations between binding potential and Positive and Negative Syndrome Scale scores were also examined. RESULTS Multivariate analysis of covariance demonstrated a significant effect of diagnosis (schizophrenia and control) on the binding potential ratio (P=.018), although the effects of diagnosis on binding potential values obtained with either [11C]raclopride or [11C]MNPA were nonsignificant. Posthoc test showed that the binding potential ratio was significantly higher in the putamen of patients (P=.017). The Positive and Negative Syndrome Scale "depressed" factor in patients was positively correlated with binding potential values of both ligands in the caudate. CONCLUSIONS The present study indicates the possibilities of: (1) a higher proportion of D2High in the putamen despite unaltered amounts of total dopamine D2 receptors; and (2) associations between depressive symptoms and amounts of caudate dopamine D2 receptors in patients with schizophrenia.
Collapse
Affiliation(s)
- Manabu Kubota
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Tomohisa Nagashima
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Harumasa Takano
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Fumitoshi Kodaka
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Hironobu Fujiwara
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Keisuke Takahata
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Sho Moriguchi
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Yasuyuki Kimura
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Makoto Higuchi
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Yoshiro Okubo
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Hidehiko Takahashi
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Hiroshi Ito
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito)
| | - Tetsuya Suhara
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Kubota, Nagashima, Takano, Kodaka, Fujiwara, Moriguchi, Kimura, Higuchi, Takahashi, Ito, and Suhara); Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (Dr Kodaka); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura); Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Dr Okubo); Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan (Dr Takahashi); Department of Radiology, School of Medicine, Fukushima Medical University, Fukushima, Japan (Dr Ito).,Correspondence: Tetsuya Suhara, MD, PhD, Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263–8555, Japan ()
| |
Collapse
|
19
|
Salmas RE, Seeman P, Aksoydan B, Erol I, Kantarcioglu I, Stein M, Yurtsever M, Durdagi S. Analysis of the Glutamate Agonist LY404,039 Binding to Nonstatic Dopamine Receptor D2 Dimer Structures and Consensus Docking. ACS Chem Neurosci 2017; 8:1404-1415. [PMID: 28272861 DOI: 10.1021/acschemneuro.7b00070] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Dopamine receptor D2 (D2R) plays an important role in the human central nervous system and is a focal target of antipsychotic agents. The D2HighR and D2LowR dimeric models previously developed by our group are used to investigate the prediction of binding affinity of the LY404,039 ligand and its binding mechanism within the catalytic domain. The computational data obtained using molecular dynamics simulations fit well with the experimental results. The calculated binding affinities of LY404,039 using MM/PBSA for the D2HighR and D2LowR targets were -12.04 and -9.11 kcal/mol, respectively. The experimental results suggest that LY404,039 binds to D2HighR and D2LowR with binding affinities (Ki) of 8.2 and 1640 nM, respectively. The high binding affinity of LY404,039 in terms of binding to [3H]domperidone was inhibited by the presence of a guanine nucleotide, indicating an agonist action of the drug at D2HighR. The interaction analysis demonstrated that while Asp114 was among the most critical amino acids for D2HighR binding, residues Ser193 and Ser197 were significantly more important within the binding cavity of D2LowR. Molecular modeling analyses are extended to ensemble docking as well as structure-based pharmacophore model (E-pharmacophore) development using the bioactive conformation of LY404,039 at the binding pocket as a template and screening of small-molecule databases with derived pharmacophore models.
Collapse
Affiliation(s)
- Ramin Ekhteiari Salmas
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, 34349 Istanbul, Turkey
| | - Philip Seeman
- Departments
of Pharmacology and Psychiatry, University of Toronto, 260 Heath
Street West, Unit 605, Toronto, Ontario M5P 3L6, Canada
| | - Busecan Aksoydan
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, 34349 Istanbul, Turkey
| | - Ismail Erol
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, 34349 Istanbul, Turkey
- Department
of Chemistry, Gebze Technical University, 41400, Kocaeli, Turkey
| | - Isik Kantarcioglu
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, 34349 Istanbul, Turkey
| | - Matthias Stein
- Max-Planck Institute for Dynamics of Complex Technical Systems, Molecular Simulations and Design Group, Sandtorstrasse 1, 39106 Magdeburg, Germany
| | - Mine Yurtsever
- Department
of Chemistry, Istanbul Technical University, 34469 Istanbul, Turkey
| | - Serdar Durdagi
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, 34349 Istanbul, Turkey
| |
Collapse
|
20
|
Ekhteiari Salmas R, Seeman P, Aksoydan B, Stein M, Yurtsever M, Durdagi S. Biological Insights of the Dopaminergic Stabilizer ACR16 at the Binding Pocket of Dopamine D2 Receptor. ACS Chem Neurosci 2017; 8:826-836. [PMID: 28001043 DOI: 10.1021/acschemneuro.6b00396] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
The dopamine D2 receptor (D2R) plays an important part in the human central nervous system and it is considered to be a focal target of antipsychotic agents. It is structurally modeled in active and inactive states, in which homodimerization reaction of the D2R monomers is also applied. The ASP2314 (also known as ACR16) ligand, a D2R stabilizer, is used in tests to evaluate how dimerization and conformational changes may alter the ligand binding space and to provide information on alterations in inhibitory mechanisms upon activation. The administration of the D2R agonist ligand ACR16 [3H](+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol ((+)PHNO) revealed Ki values of 32 nM for the D2highR and 52 μM for the D2lowR. The calculated binding affinities of ACR16 with post processing molecular dynamics (MD) simulations analyses using MM/PBSA for the monomeric and homodimeric forms of the D2highR were -9.46 and -8.39 kcal/mol, respectively. The data suggests that the dimerization of the D2R leads negative cooperativity for ACR16 binding. The dimerization reaction of the D2highR is energetically favorable by -22.95 kcal/mol. The dimerization reaction structurally and thermodynamically stabilizes the D2highR conformation, which may be due to the intermolecular forces formed between the TM4 of each monomer, and the result strongly demonstrates dimerization essential for activation of the D2R.
Collapse
Affiliation(s)
- Ramin Ekhteiari Salmas
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, Istanbul, Turkey
| | - Philip Seeman
- Departments
of Pharmacology and Psychiatry, University of Toronto, 260 Heath
Street West, Unit 605, M5P 3L6 Toronto, Ontario Canada
| | - Busecan Aksoydan
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, Istanbul, Turkey
| | - Matthias Stein
- Max-Planck
Institute
for Dynamics of Complex Technical Systems, Molecular Simulations and
Design Group, Sandtorstrasse 1, 39106 Magdeburg, Germany
| | - Mine Yurtsever
- Department
of Chemistry, Istanbul Technical University, 34467 Istanbul, Turkey
| | - Serdar Durdagi
- Computational
Biology and Molecular Simulations Laboratory, Department of Biophysics,
School of Medicine, Bahcesehir University, Istanbul, Turkey
| |
Collapse
|
21
|
Yin J, Barr AM, Ramos-Miguel A, Procyshyn RM. Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. Curr Neuropharmacol 2017; 15:174-183. [PMID: 27264948 PMCID: PMC5327459 DOI: 10.2174/1570159x14666160606093602] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 05/16/2016] [Accepted: 05/31/2016] [Indexed: 02/06/2023] Open
Abstract
Chronic prescription of antipsychotics seems to lose its therapeutic benefits in the prevention of recurring psychotic symptoms. In many instances, the occurrence of relapse from initial remission is followed by an increase in dose of the prescribed antipsychotic. The current understanding of why this occurs is still in its infancy, but a controversial idea that has regained attention recently is the notion of iatrogenic dopamine supersensitivity. Studies on cell cultures and animal models have shown that long-term antipsychotic use is linked to both an upregulation of dopamine D<sub>2</sub>-receptors in the striatum and the emergence of enhanced receptor affinity to endogenous dopamine. These findings have been hypothesized to contribute to the phenomenon known as dopamine supersensitivity psychosis (DSP), which has been clinically typified as the foundation of rebound psychosis, drug tolerance, and tardive dyskinesia. The focus of this review is the update of evidence behind the classification of antipsychotic induced DSP and an investigation of its relationship to treatment resistance. Since antipsychotics are the foundation of illness management, a greater understanding of DSP and its prevention may greatly affect patient outcomes.
Collapse
Affiliation(s)
- John Yin
- Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, B.C., V6T 1Z3, Canada;
| | - Alasdair M. Barr
- Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, B.C., V6T 1Z3, Canada;
| | - Alfredo Ramos-Miguel
- Department of Psychiatry, University of British Columbia, Vancouver, B.C., V6T 2A1, Canada
| | - Ric M. Procyshyn
- Department of Psychiatry, University of British Columbia, Vancouver, B.C., V6T 2A1, Canada
| |
Collapse
|
22
|
Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies DL. Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors. J Neurochem 2016; 139:134-48. [PMID: 27402173 DOI: 10.1111/jnc.13734] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Revised: 06/26/2016] [Accepted: 06/28/2016] [Indexed: 11/27/2022]
Abstract
Purinergic P2X4 receptors (P2X4Rs) belong to the P2X superfamily of ion channels regulated by ATP. We recently demonstrated that P2X4R knockout (KO) mice exhibited deficits in sensorimotor gating, social interaction, and ethanol drinking behavior. Dopamine (DA) dysfunction may underlie these behavioral changes, but there is no direct evidence for P2X4Rs' role in DA neurotransmission. To test this hypothesis, we measured markers of DA function and dependent behaviors in P2X4R KO mice. P2X4R KO mice exhibited altered density of pre-synaptic markers including tyrosine hydroxylase, dopamine transporter; post-synaptic markers including dopamine receptors and phosphorylation of downstream targets including dopamine and cyclic-AMP regulated phosphoprotein of 32 kDa and cyclic-AMP-response element binding protein in different parts of the striatum. Ivermectin, an allosteric modulator of P2X4Rs, significantly affected dopamine and cyclic AMP regulated phosphoprotein of 32 kDa and extracellular regulated kinase1/2 phosphorylation in the striatum. Sensorimotor gating deficits in P2X4R KO mice were rescued by DA antagonists. Using the 6-hydroxydopamine model of DA depletion, P2X4R KO mice exhibited an attenuated levodopa (L-DOPA)-induced motor behavior, whereas ivermectin enhanced this behavior. Collectively, these findings identified an important role for P2X4Rs in maintaining DA homeostasis and illustrate how this association is important for CNS functions including motor control and sensorimotor gating. We propose that P2X4 receptors (P2X4Rs) regulate dopamine (DA) homeostasis and associated behaviors. Pre-synaptic and post-synaptic DA markers were significantly altered in the dorsal and ventral striatum of P2X4R KO mice, implicating altered DA neurotransmission. Sensorimotor gating deficits in P2X4R KO mice were rescued by DA antagonists. Ivermectin (IVM), a positive modulator of P2X4Rs, enhanced levodopa (L-DOPA)-induced motor behavior. These studies highlight potential interactions between P2X4Rs and DA system.
Collapse
Affiliation(s)
- Sheraz Khoja
- Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA
| | - Vivek Shah
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Damaris Garcia
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Liana Asatryan
- Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California, USA
| | - Michael W Jakowec
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Daryl L Davies
- Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California, USA.
| |
Collapse
|
23
|
Sander CY, Hooker JM, Catana C, Rosen BR, Mandeville JB. Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI. Neuropsychopharmacology 2016; 41:1427-36. [PMID: 26388148 PMCID: PMC4793127 DOI: 10.1038/npp.2015.296] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 09/14/2015] [Accepted: 09/14/2015] [Indexed: 12/23/2022]
Abstract
This study investigated the dynamics of dopamine receptor desensitization and internalization, thereby proposing a new technique for non-invasive, in vivo measurements of receptor adaptations. The D2/D3 agonist quinpirole, which induces receptor internalization in vitro, was administered at graded doses in non-human primates while imaging with simultaneous positron emission tomography (PET) and functional magnetic resonance imaging (fMRI). A pronounced temporal divergence between receptor occupancy and fMRI signal was observed: occupancy remained elevated while fMRI responded transiently. Analogous experiments with an antagonist (prochlorperazine) and a lower-affinity agonist (ropinirole) exhibited reduced temporal dissociation between occupancy and function, consistent with a mechanism of desensitization and internalization that depends upon drug efficacy and affinity. We postulated a model that incorporates internalization into a neurovascular-coupling relationship. This model yielded in vivo desensitization/internalization rates (0.2/min for quinpirole) consistent with published in vitro measurements. Overall, these results suggest that simultaneous PET/fMRI enables characterization of dynamic neuroreceptor adaptations in vivo, and may offer a first non-invasive method for assessing receptor desensitization and internalization.
Collapse
Affiliation(s)
- Christin Y Sander
- A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA,Harvard Medical School, Boston, MA, USA,A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Room 2301, Charlestown, MA 02129, USA, Tel: +617 724 1839, Fax: +617 726 7422, E-mail:
| | - Jacob M Hooker
- A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA,Harvard Medical School, Boston, MA, USA
| | - Ciprian Catana
- A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA,Harvard Medical School, Boston, MA, USA
| | - Bruce R Rosen
- A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA,Harvard Medical School, Boston, MA, USA,Health Sciences and Technology, Harvard-MIT, Cambridge, MA, USA
| | - Joseph B Mandeville
- A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA,Harvard Medical School, Boston, MA, USA
| |
Collapse
|
24
|
Nørbak-Emig H, Ebdrup BH, Fagerlund B, Svarer C, Rasmussen H, Friberg L, Allerup PN, Rostrup E, Pinborg LH, Glenthøj BY. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. Int J Neuropsychopharmacol 2016; 19:pyw006. [PMID: 26819282 PMCID: PMC4886673 DOI: 10.1093/ijnp/pyw006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 01/18/2016] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND We have previously reported associations between frontal D2/3 receptor binding potential positive symptoms and cognitive deficits in antipsychotic-naïve schizophrenia patients. Here, we examined the effect of dopamine D2/3 receptor blockade on cognition. Additionally, we explored the relation between frontal D2/3 receptor availability and treatment effect on positive symptoms. METHODS Twenty-five antipsychotic-naïve first-episode schizophrenia patients were examined with the Positive and Negative Syndrome Scale, tested with the cognitive test battery Cambridge Neuropsychological Test Automated Battery, scanned with single-photon emission computerized tomography using the dopamine D2/3 receptor ligand [(123)I]epidepride, and scanned with MRI. After 3 months of treatment with either risperidone (n=13) or zuclopenthixol (n=9), 22 patients were reexamined. RESULTS Blockade of extrastriatal dopamine D2/3 receptors was correlated with decreased attentional focus (r = -0.615, P=.003) and planning time (r = -0.436, P=.048). Moreover, baseline frontal dopamine D2/3 binding potential and positive symptom reduction correlated positively (D2/3 receptor binding potential left frontal cortex rho = 0.56, P=.003; D2/3 receptor binding potential right frontal cortex rho = 0.48, P=.016). CONCLUSIONS Our data support the hypothesis of a negative influence of D2/3 receptor blockade on specific cognitive functions in schizophrenia. This is highly clinically relevant given the well-established association between severity of cognitive disturbances and a poor functional outcome in schizophrenia. Additionally, the findings support associations between frontal D2/3 receptor binding potential at baseline and the effect of antipsychotic treatment on positive symptoms.
Collapse
Affiliation(s)
- Henrik Nørbak-Emig
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Bjørn H Ebdrup
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Birgitte Fagerlund
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Claus Svarer
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Hans Rasmussen
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Lars Friberg
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Peter N Allerup
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Egill Rostrup
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Lars H Pinborg
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg)
| | - Birte Y Glenthøj
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Mental Health Centre Glostrup, Mental Health Services, Capital Region of Denmark, Glostrup, Denmark (Drs Nørbak-Emig, Ebdrup, Fagerlund, Rasmussen, and Glenthøj); University of Copenhagen, Faculty of Health and Medical Sciences, Department of Clinical Medicine, Copenhagen, Denmark (Drs Nørbak-Emig and Glenthøj); Neurobiology Research Unit and Epilepsy Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (Drs Svarer and Pinborg); Department of Education, Centre for Research in Compulsory Schooling, Aarhus University, Denmark (Dr Allerup); Functional Imaging Unit, Department of Diagnostics, Copenhagen University Hospital, Glostrup Hospital, Denmark (Dr Rostrup); Department of Clinical Physiology and Nuclear Medicine, Copenhagen University, Bispebjerg Hospital, Denmark (Dr Friberg).
| |
Collapse
|
25
|
Oda Y, Kanahara N, Iyo M. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia. Int J Mol Sci 2015; 16:30144-63. [PMID: 26694375 PMCID: PMC4691170 DOI: 10.3390/ijms161226228] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 12/01/2015] [Accepted: 12/08/2015] [Indexed: 12/22/2022] Open
Abstract
Although the dopamine D2 receptor (DRD2) has been a main target of antipsychotic pharmacotherapy for the treatment of schizophrenia, the standard treatment does not offer sufficient relief of symptoms to 20%-30% of patients suffering from this disorder. Moreover, over 80% of patients experience relapsed psychotic episodes within five years following treatment initiation. These data strongly suggest that the continuous blockade of DRD2 by antipsychotic(s) could eventually fail to control the psychosis in some point during long-term treatment, even if such treatment has successfully provided symptomatic improvement for the first-episode psychosis, or stability for the subsequent chronic stage. Dopamine supersensitivity psychosis (DSP) is historically known as a by-product of antipsychotic treatment in the manner of tardive dyskinesia or transient rebound psychosis. Numerous data in psychopharmacological studies suggest that the up-regulation of DRD2, caused by antipsychotic(s), is likely the mechanism underlying the development of the dopamine supersensitivity state. However, regardless of evolving notions of dopamine signaling, particularly dopamine release, signal transduction, and receptor recycling, most of this research has been conducted and discussed from the standpoint of disease etiology or action mechanism of the antipsychotic, not of DSP. Hence, the mechanism of the DRD2 up-regulation or mechanism evoking clinical DSP, both of which are caused by pharmacotherapy, remains unknown. Once patients experience a DSP episode, they become increasingly difficult to treat. Light was recently shed on a new aspect of DSP as a treatment-resistant factor. Clarification of the detailed mechanism of DSP is therefore crucial, and a preventive treatment strategy for DSP or treatment-resistant schizophrenia is urgently needed.
Collapse
Affiliation(s)
- Yasunori Oda
- Department of Psychiatry, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan.
| | - Nobuhisa Kanahara
- Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan.
| | - Masaomi Iyo
- Department of Psychiatry, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan.
| |
Collapse
|
26
|
Oda Y, Tadokoro S, Takase M, Kanahara N, Watanabe H, Shirayama Y, Hashimoto K, Iyo M. G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. J Psychopharmacol 2015; 29:1308-13. [PMID: 26174132 DOI: 10.1177/0269881115593903] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
In humans, long-term antipsychotic treatment is known to induce movement disorders and a psychosis, called dopamine supersensitivity psychosis (DSP). The mechanism by which chronic administration of antipsychotic(s) causes DSP may be the treatment-induced up-regulation of dopamine D2 receptors (DRD2). G protein-coupled receptor kinase 6 (GRK6) and beta-arrestin 2 (ARRB2) play important roles in the trafficking of DRD2 by phosphorylation and internalization. We investigated the effects of chronic continuous treatment with mini-pump-administered haloperidol (HAL) on the sensitivity of Wistar rats to dopamine, as measured by the locomotor response to methamphetamine (MAP) and the density of striatal DRD2. Chronic continuous treatment with HAL resulted in significantly higher locomotor response to MAP and significantly higher striatal DRD2 density compared with those in rats administered vehicle (VEH). Enzyme-linked immunosorbent assays revealed that striatal ARRB2 in DSP model rats tended to decrease in comparison with that in the VEH group. In addition, the ratio of GRK6/ARRB2 in DSP model rats was significantly higher than that in controls. Our results suggest that alterations of the GRK6 and ARRB2 system could induce both DRD2 up-regulation and impairment of the dopamine signaling pathway, resulting potentially in the development of DSP.
Collapse
Affiliation(s)
- Yasunori Oda
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
| | | | - Masayuki Takase
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
| | - Nobuhisa Kanahara
- Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Chiba, Japan
| | - Hiroyuki Watanabe
- Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Chiba, Japan
| | - Yukihiko Shirayama
- Department of Psychiatry, Teikyo University Chiba Medical Center, Ichihara, Japan
| | - Kenji Hashimoto
- Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
| | - Masaomi Iyo
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
| |
Collapse
|
27
|
Areal LB, Rodrigues LCM, Andrich F, Moraes LS, Cicilini MA, Mendonça JB, Pelição FS, Nakamura-Palacios EM, Martins-Silva C, Pires RGW. Behavioural, biochemical and molecular changes induced by chronic crack-cocaine inhalation in mice: The role of dopaminergic and endocannabinoid systems in the prefrontal cortex. Behav Brain Res 2015; 290:8-16. [PMID: 25940765 DOI: 10.1016/j.bbr.2015.04.036] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Revised: 04/16/2015] [Accepted: 04/22/2015] [Indexed: 01/17/2023]
Abstract
Crack-cocaine addiction has increasingly become a public health problem worldwide, especially in developing countries. However, no studies have focused on neurobiological mechanisms underlying the severe addiction produced by this drug, which seems to differ from powder cocaine in many aspects. This study investigated behavioural, biochemical and molecular changes in mice inhaling crack-cocaine, focusing on dopaminergic and endocannabinoid systems in the prefrontal cortex. Mice were submitted to two inhalation sessions of crack-cocaine a day (crack-cocaine group) during 11 days, meanwhile the control group had no access to the drug. We found that the crack-cocaine group exhibited hyperlocomotion and a peculiar jumping behaviour ("escape jumping"). Blood collected right after the last inhalation session revealed that the anhydroecgonine methyl ester (AEME), a specific metabolite of cocaine pyrolysis, was much more concentrated than cocaine itself in the crack-cocaine group. Most genes related to the endocannabinoid system, CB1 receptor and cannabinoid degradation enzymes were downregulated after 11-day crack-cocaine exposition. These changes may have decreased dopamine and its metabolites levels, which in turn may be related with the extreme upregulation of dopamine receptors and tyrosine hydroxylase observed in the prefrontal cortex of these animals. Our data suggest that after 11 days of crack-cocaine exposure, neuroadaptive changes towards downregulation of reinforcing mechanisms may have taken place as a result of neurochemical changes observed on dopaminergic and endocannabinoid systems. Successive changes like these have never been described in cocaine hydrochloride models before, probably because AEME is only produced by cocaine pyrolysis and this metabolite may underlie the more aggressive pattern of addiction induced by crack-cocaine.
Collapse
Affiliation(s)
- Lorena B Areal
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil; Laboratory of Molecular and Behavioral Neurobiology, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil
| | - Livia C M Rodrigues
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil; Laboratory of Cognitive Sciences and Neuropsychopharmacology, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil
| | - Filipe Andrich
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil; Laboratory of Molecular and Behavioral Neurobiology, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil
| | - Livia S Moraes
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil; Laboratory of Molecular and Behavioral Neurobiology, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil
| | - Maria A Cicilini
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil
| | - Josideia B Mendonça
- Laboratory of Forensic Science Service, Espirito Santo State Police, Av. Nossa Senhora. da Penha, 2290, Vitória-ES 29045-402, Brazil
| | - Fabricio S Pelição
- Laboratory of Forensic Science Service, Espirito Santo State Police, Av. Nossa Senhora. da Penha, 2290, Vitória-ES 29045-402, Brazil
| | - Ester M Nakamura-Palacios
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil; Laboratory of Cognitive Sciences and Neuropsychopharmacology, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil
| | - Cristina Martins-Silva
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil; Laboratory of Molecular and Behavioral Neurobiology, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil
| | - Rita G W Pires
- Department of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil; Laboratory of Molecular and Behavioral Neurobiology, Health Sciences Center, Federal University of Espirito Santo, Av. Marechal Campos 1468 - Maruípe, Vitoria-ES 29.043-910, Brazil.
| |
Collapse
|
28
|
Biskup CS, Gaber T, Helmbold K, Bubenzer-Busch S, Zepf FD. Amino acid challenge and depletion techniques in human functional neuroimaging studies: an overview. Amino Acids 2015; 47:651-83. [DOI: 10.1007/s00726-015-1919-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Accepted: 01/09/2015] [Indexed: 01/16/2023]
|
29
|
Podder A, Latha N. New Insights into Schizophrenia Disease Genes Interactome in the Human Brain: Emerging Targets and Therapeutic Implications in the Postgenomics Era. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY 2014; 18:754-66. [DOI: 10.1089/omi.2014.0082] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Avijit Podder
- Bioinformatics Infrastructure Facility, Sri Venkateswara College, University of Delhi, New Delhi, India
| | - Narayanan Latha
- Bioinformatics Infrastructure Facility, Sri Venkateswara College, University of Delhi, New Delhi, India
| |
Collapse
|
30
|
van Wieringen JP, Michel MC, Janssen HM, Janssen AG, Elsinga PH, Booij J. Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. EJNMMI Res 2014; 4:53. [PMID: 25977878 PMCID: PMC4422956 DOI: 10.1186/s13550-014-0053-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Accepted: 09/23/2014] [Indexed: 01/11/2023] Open
Abstract
Background Dopamine D2/3 receptor (D2/3R) agonist radiopharmaceuticals are considered superior to antagonists to detect dopamine release, e.g. induced by amphetamines. Agonists bind preferentially to the high-affinity state of the dopamine D2R, which has been proposed as the reason why agonists are more sensitive to detect dopamine release than antagonist radiopharmaceuticals, but this theory has been challenged. Interestingly, not all agonists similarly activate the classic cyclic adenosine mono phosphate (cAMP) and the ?-arrestin-2 pathway, some stimulate preferentially one of these pathways; a phenomenon called biased agonism. Because these pathways can be affected separately by pathologies or drugs (including dopamine releasers), it is important to know how agonist radiotracers act on these pathways. Therefore, we characterized the intracellular signalling of the well-known D2/3R agonist radiopharmaceuticals NPA and PHNO and of several novel D2/3R agonists. Methods cAMP accumulation and ?-arrestin-2 recruitment were measured on cells expressing human D2R. Results All tested agonists showed (almost) full agonism in both pathways. Conclusions The tested D2/3R agonist radiopharmaceuticals did not exhibit biased agonism in vitro. Consequently, it is likely that drugs (including psychostimulants like amphetamines) and/or pathologies that influence the cAMP and/or the ?-arrestin-2 pathway may influence the binding of these radiopharmaceuticals.
Collapse
Affiliation(s)
- Jan-Peter van Wieringen
- Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105, AZ, The Netherlands
| | - Martin C Michel
- Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany
| | | | | | - Philip H Elsinga
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Jan Booij
- Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105, AZ, The Netherlands
| |
Collapse
|
31
|
Milan L, Barrière G, De Deurwaerdère P, Cazalets JR, Bertrand SS. Monoaminergic control of spinal locomotor networks in SOD1G93A newborn mice. Front Neural Circuits 2014; 8:77. [PMID: 25071458 PMCID: PMC4081764 DOI: 10.3389/fncir.2014.00077] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2014] [Accepted: 06/18/2014] [Indexed: 12/11/2022] Open
Abstract
Mutations in the gene that encodes Cu/Zn-superoxide dismutase (SOD1) are the cause of approximately 20% of familial forms of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. While ALS symptoms appear in adulthood, spinal motoneurons exhibit functional alterations as early as the embryonic and postnatal stages in the murine model of ALS, the SOD1 mice. Monoaminergic - i.e., dopaminergic (DA), serotoninergic (5-HT), and noradrenergic (NA) - pathways powerfully control spinal networks and contribute significantly to their embryonic and postnatal maturation. Alterations in monoaminergic neuromodulation during development could therefore lead to impairments in the motoneuronal physiology. In this study, we sought to determine whether the monoaminergic spinal systems are modified in the early stages of development in SOD1 mice. Using a post-mortem analysis by high performance liquid chromatography (HPLC), monoaminergic neuromodulators and their metabolites were quantified in the lumbar spinal cord of SOD1 and wild-type (WT) mice aged one postnatal day (P1) and P10. This analysis underscores an increased content of DA in the SOD1 lumbar spinal cord compared to that of WT mice but failed to reveal any modification of the other monoaminergic contents. In a next step, we compared the efficiency of the monoaminergic compounds in triggering and modulating fictive locomotion in WT and SOD1 mice. This study was performed in P1-P3 SOD1 mice and age-matched control littermates using extracellular recordings from the lumbar ventral roots in the in vitro isolated spinal cord preparation. This analysis revealed that the spinal networks of SOD1(G93A) mice could generate normal locomotor activity in the presence of NMA-5-HT. Interestingly, we also observed that SOD1 spinal networks have an increased sensitivity to NA compared to WT spinal circuits but exhibited similar DA responses.
Collapse
Affiliation(s)
- Léa Milan
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR5287, Université de Bordeaux Bordeaux, France
| | - Grégory Barrière
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR5287, Université de Bordeaux Bordeaux, France
| | | | - Jean-René Cazalets
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR5287, Université de Bordeaux Bordeaux, France
| | - Sandrine S Bertrand
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR5287, Université de Bordeaux Bordeaux, France
| |
Collapse
|
32
|
Blum K, Oscar-Berman M, Badgaiyan RD, Palomo T, Gold MS. Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. Med Hypotheses 2014; 82:606-14. [PMID: 24636783 PMCID: PMC4039414 DOI: 10.1016/j.mehy.2014.02.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Revised: 02/12/2014] [Accepted: 02/17/2014] [Indexed: 01/05/2023]
Abstract
The dopamine system has been implicated in both substance use disorder (SUD) and schizophrenia. A recent meta-analysis suggests that A1 allele of the DRD2 gene imposes genetic risk for SUD, especially alcoholism and has been implicated in Reward Deficiency Syndrome (RDS). We hypothesize that dopamine D2 receptor (DRD2) gene Taq1 A2 allele is associated with a subtype of non-SUD schizophrenics and as such may act as a putative protective agent against the development of addiction to alcohol or other drugs of abuse. Schizophrenics with SUD may be carriers of the DRD2 Taq1 A1 allele, and/or other RDS reward polymorphisms and have hypodopaminergic reward function. One plausible mechanism for alcohol seeking in schizophrenics with SUD, based on previous research, may be a deficiency of gamma type endorphins that has been linked to schizophrenic type psychosis. We also propose that alcohol seeking behavior in schizophrenics, may serve as a physiological self-healing process linked to the increased function of the gamma endorphins, thereby reducing abnormal dopaminergic activity at the nucleus accumbens (NAc). These hypotheses warrant further investigation and cautious interpretation. We, therefore, encourage research involving neuroimaging, genome wide association studies (GWAS), and epigenetic investigation into the relationship between neurogenetics and systems biology to unravel the role of dopamine in psychiatric illness and SUD.
Collapse
Affiliation(s)
- Kenneth Blum
- Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA; Department of Clinical Neurology, Path Research Foundation, New York, NY, USA; Department of Genomics, IGENE, LLC, Austin, TX, USA; Department of Psychiatry, Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science, College of Medicine, Burlington, VT, USA; Dominion Diagnostics, LLC, North Kingstown, RI, USA; Department of Addiction Research & Therapy, Malibu Beach Recovery Center, Malibu Beach, CA, USA; RD Solutions, LLC, Research Center, Austin, TX, USA; Department of Nutrigenomics, RD Solutions, LLC, La Jolla, CA, USA.
| | - Marlene Oscar-Berman
- Departments of Psychiatry and Anatomy & Neurobiology, Boston University School of Medicine and Boston VA Healthcare System, Boston, MA, USA
| | - Rajendra D Badgaiyan
- Department of Psychiatry and Neuroimaging Laboratory, SUNY-at Buffalo, Buffalo, NY, USA
| | - Tomas Palomo
- Unidad de Alcoholismo y Patología Dual, Servicio de Psiquiatría, Hospital Universitario 12 de Octubre, Av. de Córdoba s/n, Madrid E-28041, Spain
| | - Mark S Gold
- Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA
| |
Collapse
|
33
|
Seeman MV, Seeman P. Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog Neuropsychopharmacol Biol Psychiatry 2014; 48:155-60. [PMID: 24128684 PMCID: PMC3858317 DOI: 10.1016/j.pnpbp.2013.10.003] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Revised: 10/03/2013] [Accepted: 10/03/2013] [Indexed: 12/22/2022]
Abstract
Adolf Meyer (1866-1950) did not see schizophrenia as a discrete disorder with a specific etiology but, rather, as a reaction to a wide variety of biopsychosocial factors. He may have been right. Today, we have evidence that gene mutations, brain injury, drug use (cocaine, amphetamine, marijuana, phencyclidine, and steroids), prenatal infection and malnutrition, social isolation and marginalization, can all result in the signs and symptoms of schizophrenia. This clinical picture is generally associated with supersensitivity to dopamine, and activates dopamine neurotransmission that is usually alleviated or blocked by drugs that block dopamine D2 receptors. While the dopamine neural pathway may be a final common route to many of the clinical symptoms, the components of this pathway, such as dopamine release and number of D2 receptors, are approximately normal in schizophrenia patients who are in remission. Postmortem findings, however, reveal more dimers of D1D2 and D2D2 receptors in both human schizophrenia brains and in animal models of schizophrenia. Another finding in animal models is an elevation of high-affinity state D2High receptors, but no radioactive ligand is yet available to selectively label D2High receptors in humans. It is suggested that synaptic dopamine supersensitivity in schizophrenia is an attempt at compensation for the original damage by heightening dopamine neurotransmission pathways (preparing the organism for fight or flight). The dopamine overactivity is experienced subjectively as overstimulation, which accounts for some of the clinical symptoms, with attempts at dampening down the stimulation leading to still other symptoms. Reaction and counter-reaction may explain the symptoms of schizophrenia.
Collapse
Affiliation(s)
- Mary V. Seeman
- Departments of Psychiatry, University of Toronto, 260 Heath St. West, Suite 605, Toronto, Ontario M5P 3L6, Canada
| | - Philip Seeman
- Departments of Pharmacology, University of Toronto, 260 Heath St. West, Suite 605, Toronto, Ontario M5P 3L6, Canada,Corresponding author. Tel.: +1 416 486 3456. (P. Seeman)
| |
Collapse
|
34
|
Madularu D, Shams WM, Brake WG. Estrogen potentiates the behavioral and nucleus accumbens dopamine response to continuous haloperidol treatment in female rats. Eur J Neurosci 2013; 39:257-65. [DOI: 10.1111/ejn.12401] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 09/26/2013] [Accepted: 09/27/2013] [Indexed: 11/28/2022]
Affiliation(s)
- Dan Madularu
- Department of Psychology; Centre for Studies in Behavioural Neurobiology; Concordia University; Montreal Quebec Canada
| | - Waqqas M. Shams
- Department of Psychology; Centre for Studies in Behavioural Neurobiology; Concordia University; Montreal Quebec Canada
| | - Wayne G. Brake
- Department of Psychology; Centre for Studies in Behavioural Neurobiology; Concordia University; Montreal Quebec Canada
| |
Collapse
|